Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?

Authors

  • Sónia C. Correia,

    1. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
    2. Department of Zoology, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal
    Search for more papers by this author
  • Paula I. Moreira

    1. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
    2. Institute of Physiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
    Search for more papers by this author

Address correspondence and reprint requests to Paula I. Moreira, Center for Neuroscience and Cell Biology, Institute of Physiology, Faculty of Medicine, University of Coimbra, Coimbra 3000-354, Portugal. E-mail: venta@ci.uc.pt or pismoreira@gmail.com

Abstract

J. Neurochem. (2010) 112, 1–12.

Abstract

Neurodegenerative diseases, generally characterized by a progressive deterioration in the structure and function of the brain, represent one of the world’s major unsolved health problems. Therefore, it is urgent to discover therapeutic targets for the design of effective strategies for the treatment of these diseases. Recent findings demonstrated that the induction of the hypoxia signaling pathway with the concomitant stabilization and transcriptional activation of the transcription factor hypoxia-inducible factor 1 (HIF-1) could mediate neuroprotective events. It has been shown that HIF-1 triggers the expression of genes involved in oxygen transport, glycolytic metabolism, angiogenesis, cell survival, apoptosis, and others processes that can interfere with cell survival. Here, we discuss the current knowledge pertaining to the regulation of HIF signaling pathway. The potential neuroprotective role of HIF-1 induction in cerebral ischemic stroke and Alzheimer’s, Parkinson’s, and Huntington’s diseases will be also discussed. The elucidation of the mechanisms involved in HIF-1-mediated neuroprotection could be important for the development of effective therapies to mitigate or prevent neurodegenerative diseases.

Abbreviations used:
AD

Alzheimer disease

β-amyloid

BDNF

brain-derived neurotrophic factor

CBP

cAMP-response element-binding protein-binding protein

CQ

clioquinol

DA

dopamine

DFO

desferoxamine

EPO

erythropoietin

FIH-1

factor-inhibiting HIF-1

GLUT

glucose transporter

HD

Huntington disease

HIF-1

hypoxia-inducible factor 1

HRE

hypoxia-responsive element

htt

huntingtin

MCAo

middle cerebral artery occlusion

OGD

oxygen–glucose deprivation

PD

Parkinson disease

PHD

prolyl hydroxylase enzyme

ROS

reactive oxygen species

SNpc

substantia nigra pars compacta

VEGF

vascular endothelial growth factor

VHL

von Hippel–Lindau protein

Neurodegenerative disorders are characterized by a progressive decline in neurological function and neuronal cell death that frequently affects specific neural systems, implying some selective vulnerability (Przedborski et al. 2003). The etiology of most neurodegenerative disorders, including cerebral ischemic stroke and Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s (HD) diseases, is multifactorial and results from an interaction between genetic predisposition, environmental, and endogenous factors (Migliore and Coppedè 2009). In the last decades, the incidence of neurodegenerative disorders has raised significantly mainly because of a dramatic increase in life expectancy and demographic changes in the population, representing a major health problem. Therefore, it is of tremendous importance to provide new and feasible therapeutic targets and strategies to avoid the onset and progression of neurodegeneration.

Brain, as a main consumer of energy, is particularly susceptible to oxygen deprivation (hypoxia) conditions (Sharp and Bernaudin 2004). Severe and prolonged hypoxia contributes to brain damage mainly because of neuronal dysfunction and cell death (Freeman and Barone 2005). However, it has been shown that mild hypoxia of short duration protects the brain against several types of injury through the induction of adaptive mechanisms that allow the maintenance of normal physiological conditions (Sharp et al. 2004b). Hypoxia-induced tolerance through the activation of the transcription factor hypoxia-inducible factor 1α (HIF-1α) is one major pathway involved in neuroprotection (Siddiq et al. 2008). HIF-1α, a master regulator of the cellular oxygen homeostasis, is stabilized and activated by hypoxia and hypoxia-mimetic agents, such as iron chelators [desferoxamine (DFO), clioquinol (CQ)] or cobalt chloride (CoCl2), and modulates the expression of several protective target genes, including glucose transporters (GLUTs), glycolytic enzymes and angiogenic factors (Semenza 1999, 2000a).

Evidence from the literature shows that HIF-1α induction by iron chelators or CoCl2 confers protection of primary cortical neurons against cell death induced by glutathione depletion. This protection was associated with enhanced HIF-1 activity and increased expression of target genes, such as glycolytic enzymes, p21, and erythropoietin (EPO) (Zaman et al. 1999). It has been shown that HIF-1α is also an essential effector of neuroprotection mediated by the purine nucleosides, adenosine and inosine, against hypoxia in PC12 and primary cerebellar granule neurons (zur Nedden et al. 2008). Recently, it was reported that DFO reverses age-induced recognition memory deficits (de Lima et al. 2008). Moreover, DFO also reduced the oxidative damage to proteins in cortex and hippocampus (de Lima et al. 2008).

Mitochondrial transport is critical for maintenance of normal neuronal function. Recent data show that the hypoxia upregulated mitochondrial movement regulator (HUMMR), a novel mitochondrial protein, is expressed in neurons and is markedly induced by HIF-1α. Knockdown of hypoxia upregulated mitochondrial movement regulator (HUMMR) or HIF-1 function in neurons exposed to hypoxia markedly reduces mitochondrial content in axons (Li et al. 2009). Altogether, these findings suggest that HIF-1α could have a preponderant role in maintaining neuronal cell viability and function during physiological and pathophysiological conditions.

Accumulating data indicate that activation of HIF-1α could exert neuroprotective effects through the induction of intrinsic adaptive mechanisms in neuronal as well as in non-neuronal cells. This review is devoted to explore and discuss the HIF-1 signaling pathway and its regulation putting focus on the crucial role of mitochondria and reactive oxygen species (ROS). Furthermore, the potential neuroprotective role of HIF-1 induction in cerebral ischemic stroke and AD, PD, and HD will be discussed.

How is hypoxia-inducible factor 1 regulated?

The induction of HIF-1α, and the consequent expression of its target genes, activates a pivotal signaling pathway involved in molecular and cellular adaptation to hypoxia (Sharp and Bernaudin 2004). Indeed, HIF-1α regulates the expression of a wide range of genes involved in vasomotor control, angiogenesis, erythropoiesis, iron metabolism, cell cycle control, cell proliferation and death, and energy metabolism (Fig. 1) (Wang and Semenza 1993; Semenza et al. 1994; Ebert et al. 1995; Forsythe et al. 1996; O’Rourke et al. 1996; Gerber et al. 1997; Lee et al. 1997; Palmer et al. 1998; Tazuke et al. 1998; Bhattacharya et al. 1999; Feldser et al. 1999; Graven et al. 1999; Tacchini et al. 1999; Bruick 2000; Mukhopadhyay et al. 2000; Takahashi et al. 2000; Sowter et al. 2001; Kaluz et al. 2002). In the brain, it was shown that HIF-1α expression is induced by hypoxic conditions in neurons, astrocytes, and ependymal and endothelial cells (Ruscher et al. 1998; Chavez et al. 2000).

Figure 1.

 Hypoxia-inducible factor 1 (HIF-1) and its targets genes. HIF-1 is a transcriptional complex involved in molecular and cellular adaptation to hypoxia. HIF-1 regulates the expression of a wide range of genes involved in vasomotor control, angiogenesis, erythropoiesis, iron metabolism, cell cycle control, cell proliferation and death, and energy metabolism.

Hypoxia-inducible factor 1 belongs to the basic helix-loop-helix transcription factor family. It is a heterodimeric transcription factor comprised of the constitutively expressed HIF-1β subunit and the oxygen-tension-regulated HIF-1α subunit (Wang et al. 1995; Huang et al. 1996, 1998; Semenza 2002). HIF-1α accumulates in response to hypoxia and is rapidly degraded upon reoxygenation (Wang et al. 1995; Jiang et al. 1996; Salceda and Caro 1997). Under normal oxygen conditions, HIF-1α is hydroxylated at two proline residues, Pro402 and Pro564, within the oxygen-dependent degradation domain by a family of prolyl hydroxylase enzymes (PHDs) (Huang et al. 1996; Pugh et al. 1997). Hydroxylation of HIF-1α requires molecular oxygen (O2), iron in ferrous form (Fe2+), and 2-oxoglutarate as cofactors (Huang et al. 1996; Pugh et al. 1997). The requirement of iron explains the hypoxic-mimetic effects of iron chelators and iron antagonists, such as CoCl2. The hydroxylated prolines are recognized by the von Hippel–Lindau protein (VHL), which acts as the recognition component of a multiprotein ubiquitin E3 ligase complex. Then, VHL binds to both hydroxylated HIF-1α and to Elongin-C, which recruits Elongin-B and other subunits of the E3 ubiquitin ligase, targeting the HIF-1α subunit for rapid ubiquitin-mediated proteasomal degradation by the 26S proteasome (Fig. 2) (Maxwell et al. 1999; Ivan et al. 2001; Jaakkola et al. 2001; Safran and Kaelin 2003). Under hypoxic conditions or iron chelation, PHDs enzymatic inhibition abrogates HIF-1α recognition by VHL and proteasomal degradation, resulting in the HIF-1α stabilization. Consequently, HIF-1α protein translocates and accumulates in the nucleus, where dimerizes with HIF-1β subunits, and recruits the transcription co-activator p300/cAMP-response element-binding protein-binding protein (CBP), forming the active HIF complex (Carrero et al. 2000; Kung et al. 2000; Mole et al. 2001). This complex binds to the hypoxia-responsive element (HRE) in the promoter, up-regulating a repertoire of target genes, including metabolic enzymes, cytokines, growth factors, receptors, and other signaling proteins (Fig. 2) (Semenza 1999).

Figure 2.

 Schematic illustration of hypoxia-inducible factor 1 (HIF-1) regulation during normoxic and hypoxic conditions. In the presence of molecular oxygen (O2), HIF-1α is hydroxylated by prolyl hydroxylase enzymes (PHDs). The hydroxylated prolines are recognized by the von Hippel-Lindau protein (VHL), which acts as the recognition component of a multiprotein ubiquitin E3 ligase complex. VHL binds to both hydroxylated HIF-1α and to Elongin-C, which recruits Elongin-B and other subunits of the E3 ubiquitin ligase, targeting the HIF-1α subunit for ubiquitin-mediated degradation by the proteasome. Under hypoxic conditions or iron chelation, PHDs enzymatic inhibition abrogates HIF-1α recognition by VHL and proteasomal degradation, resulting in HIF-1α stabilization. Mitochondrial reactive oxygen species (ROS) also inhibits PHDs activity, preventing the hydroxylation of HIF-1α and promoting its stabilization. Consequently, HIF-1α protein translocates and accumulates in the nucleus, where dimerizes with HIF-1β subunits and recruits the transcription co-activator p300/CBP, forming the active HIF complex. This complex binds to the hypoxia-responsive element (HRE) in the promoter and activates transcription of target genes.

Mahon et al. (2001) demonstrated that HIF-1 activity is also regulated in the nucleus by factor-inhibiting HIF-1 (FIH-1). Like PHDs, FIH-1 is a member of the Fe2+ and 2-oxoglutarate-dependent dioxygenase family of hydroxylases. Under normoxia, FIH-1 hydroxylates a specific asparagine residue in the C-terminal transactivation domain of HIF-1α, which represses the transcriptional activity of HIF-1α by blocking the recruitment of the co-activator p300/CBP (Hewitson et al. 2002; Lando et al. 2002; McNeill et al. 2002; Lee et al. 2003; Koivunen et al. 2004). Hypoxia inhibits FIH-1 activity allowing the binding of HIF-1α to p300/CBP and the transcription of HIF-1 target genes.

Mitochondria and ROS: important players in HIF-1 stabilization?

Mitochondria are one of the major producers of ROS and are also the main targets of oxidative damage, mitochondrial dysfunction and exacerbated ROS production being generally associated with several pathological conditions, including neurodegenerative disorders (Lin and Beal 2006; Moreira et al. 2006a, 2007, 2009). However, accumulating evidence indicates that, under physiological conditions, mitochondria function as signaling organelles and regulate various intracellular processes through the generation of moderate ROS levels (Zhang and Gutterman 2007). Indeed, mitochondria have been implicated in the transduction of hypoxic signal, mitochondrial ROS being the putative signaling molecules between a cellular O2-sensor and HIF-1.

Previous studies established a relationship between mitochondrial electron transport chain and HIF-1α stabilization. Indeed, it has been shown that pharmacological inhibitors of the mitochondrial electron transport chain (rotenone, myxothiazol, and stigmatellin) block the hypoxic stabilization of HIF-1α (Chandel et al. 1998, 2000; Agani et al. 2000). Accordingly, it was shown that genetic deletions of mitochondrial complex I also blocked HIF-1α stabilization (DeHaan et al. 2004). Recent studies suggested that mitochondrial ROS are essential to HIF-1α protein stabilization and activation (Klimova and Chandel 2008). Additionally, Bell et al. (2007) demonstrated the crucial role of ROS generated by the Q0 site of complex III in the hypoxia-mediated survival signaling. Under hypoxic conditions, the generation of mitochondrial ROS prevents the hydroxylation of HIF-1α, thereby stabilizing HIF-1α and allowing the translocation to the nucleus and dimerization with HIF-1β, initiating the transcription of target genes (Fig. 2) (Brunelle et al. 2005; Guzy et al. 2005; Mansfield et al. 2005; Bell et al. 2007). In addition, several studies show that exogenous application of hydrogen peroxide (H2O2) can induce HIF-α under normoxic conditions and ROS scavengers can block hypoxic induction of HIF (Guzy et al. 2005; Mansfield et al. 2005). Moreover, an in vitro study demonstrated that under hypoxic conditions (3% O2) mitoubiquinone, a mitochondria-targeted antioxidant, ablated the hypoxic induction of ROS generation and destabilized HIF-1α protein, culminating in the abrogation of HIF-1 transcriptional activity (Sanjuán-Pla et al. 2005). Furthermore, Sanjuán-Pla et al. (2005) showed that pharmacological intervention using hypoxia-mimetic agents (DFO and CoCl2), which are not thought to involve mitochondrial ROS, stabilized HIF-1α independently of mitoubiquinone, suggesting that mitochondrial ROS are intrinsically linked to HIF-1α expression during hypoxia. In addition, Chandel et al. (1998, 2000) showed that mitochondrial DNA-depleted (ρ0) cells, without a functional mitochondrial respiratory chain, failed to increase ROS generation and HIF-1α accumulation under hypoxic conditions. The same authors also showed that low levels of exogenous H2O2 (40 μM) stabilize HIF-1α protein during normoxia and increase HRE-luciferase expression in ρ0 cells (Chandel et al. 2000). In contrast, a previous in vitro study demonstrated that exposure of HeLa cells to H2O2 (0.1–1 mM) selectively blocked accumulation of HIF-1α protein (Huang et al. 1996). Moreover, other studies also show that ρ0 cells are still able to stabilize HIF-1α proteins levels (Srinivas et al. 2001; Vaux et al. 2001).

Growing evidence suggest that mitochondria and ROS are involved in HIF-1-mediated protective events. It was observed that preconditioning by moderate ROS-stimulation protects cultured neurons against different damaging agents and prevents against the subsequent massive oxygen radical formation (Ravati et al. 2000). Moreover, it was reported that hypoxic preconditioning-induced neuroprotection is associated with ROS production and subsequent induction of HIF-1 and its downstream gene EPO (Liu et al. 2005). Chang et al. (2008) reported that low levels of exogenous H2O2 increase HIF-1α expression and protects against ischemia in primary cortical neurons. In addition, it was demonstrated that in primary cultured neurons preconditioned with brief oxygen–glucose deprivation (OGD), H2O2 is the main trigger involved in the mechanism of preconditioning-induced neuronal protection (Furuichi et al. 2005). A recent in vivo study shows that ROS may be involved in the increase of mRNA of HIF-1α and its target genes in human leukocytes (Pialoux et al. 2009). Additionally, Kuroki et al. (1996) demonstrated that human retinal pigment epithelial cells exposed to superoxide anion (O2•−) and H2O2 rapidly increased vascular endothelial growth factor (VEGF) mRNA levels. Increased VEGF mRNA levels were also observed in cultured human melanoma and rat glioblastoma cells treated with O2•− and H2O2 (Kuroki et al. 1996).

Altogether these studies demonstrate that mitochondrial ROS can act as signaling molecules triggering protective responses through HIF-1α activation, which suggests that mitochondria could be a promising therapeutic target to manipulate HIF-1-mediated neuroprotective effects.

Targeting HIF-1 signaling: implications for neurodegenerative disorders

It has been documented that mitochondrial dysfunction, inflammation, iron dysregulation and apoptosis have a crucial role in the pathogenesis of several neurodegenerative disorders (Zecca et al. 2004; Lin and Beal 2006; Moreira et al. 2006a, 2007, 2009; Zipp and Aktas 2006). As mentioned, HIF-1 signaling pathway is involved in several physiological responses, HIF-1 activity being correlated with the modulation of various metabolic pathways. Therefore, the activation of HIF-1 signal transduction pathway and consequent expression of its protective target genes could represent an efficient neuroprotective strategy to mitigate or prevent neurodegenerative disorders. The next section is devoted to explore the potential benefits of targeting HIF signaling pathway in the context of some neurodegenerative disorders.

Cerebral ischemic stroke

Stroke is the third leading cause of death and severe long-term disability in adults. According to the World Health Organization, 15 million people suffer stroke worldwide each year (http://www.strokecenter.org/patients/stats.htm). In cerebral ischemic stroke, the most common type of stroke, the reduction in blood supply to brain tissue results in a decrease in the availability of glucose and oxygen, which are necessary for normal brain function. Additionally, cerebral ischemic stroke triggers multiple biochemical and molecular mechanisms that impairs the neurologic functions through the breakdown of cellular integrity mediated by excitotoxicity, ionic imbalance, oxidative/nitrative stress, and DNA damage (Lo et al. 2003; Rami et al. 2008).

Accumulating evidence indicates that the induction of HIF-1 provides protection against cerebral ischemic damage. Indeed, studies using models of focal and global cerebral ischemia have shown that HIF-1α protein accumulation triggers the expression of target genes involved in various adaptive responses (Semenza 2000b; Sharp and Bernaudin 2004). Moreover, previous studies also showed that the pre-treatment or post-treatment with hypoxia-mimetic agents (DFO or CoCl2) reduced cell loss in models of focal or global ischemia in vitro and in vivo (Bergeron et al. 2000; Demougeot et al. 2004a,b; Hamrick et al. 2005). Bergeron et al. (1999) reported that focal ischemia induces HIF-1 in brain. Moreover, increased expression of HIF-1 target genes as a result of HIF-1 activation by hypoxia may contribute to tissue viability in the hypoxic/ischemic penumbra by increasing glucose transport and glycolysis (Bergeron et al. 1999). Accordingly, Sharp et al. (2001) observed that after focal cerebral ischemia, mRNAs encoding HIF-1α, GLUT-1, and several glycolytic enzymes, including lactate dehydrogenase, were up-regulated in the areas around the infarction. Moreover, HIF and its target genes were induced by 7.5 h after the onset of ischemia and increased further at 19 and 24 h. Further, preconditioning with the HIF-1 inducers CoCl2 or DFO, 24 h before the stroke, decreased infarction by 75% and 56%, respectively, compared with vehicle-injected, littermate controls. Thus, HIF-1 activation could contribute to protective brain preconditioning (Sharp et al. 2001). Baranova et al. (2007) observed that neuron-specific knockdown of HIF-1 aggravated brain damage after middle cerebral artery occlusion (MCAo) and reduced survival rate of MCAo mice. Moreover, Baranova et al. (2007) demonstrated that the pharmacologic HIF-1 activators 3,4-dihydroxybenzoic acid, deferoxamine (DFO), and 2,2-dipyridyl significantly reduced ischemic injury in wild-type mice, whereas the effectiveness of these compounds was significantly attenuated in mice with neuron-specific HIF-1α knockdown. Consistent with this report, Siddiq et al. (2005) showed that hypoxia or hypoxia-mimetic agents confer neuroprotection against oxidative death in vitro and ischemic injury in vivo through the inhibition of PHDs, and consequent HIF-1α stabilization and up-regulation of HIF-1-dependent target genes. In vivo models of ischemic stroke showed that systemic DFO reduces stroke damage when administered both prior to and after MCAo (Palmer et al. 1994; Prass et al. 2002; Mu et al. 2005; Freret et al. 2006). A recent study demonstrated that DFO induced tolerance against focal cerebral ischemia in rats, and exerted protective effect on OGD cultured cortical neurons through the induction of HIF-1α and EPO both in vivo and in vitro (Li et al. 2008). Recent findings showed that intranasal administration of DFO, a non-invasive method, prevents and treats stroke damage after MCAo in rats (Hanson et al. 2009). Zhou et al. (2008) evaluated the effect of 2-methoxyestradiol (2ME2), a natural metabolite of estrogen that inhibits HIF-1α, in global cerebral ischemia in rats. As expected, the authors observed that 2ME2 treatment significantly reduced HIF-1 levels. Moreover, it was observed that 2ME2 treatment lower neuronal cell survival, which suggests that 2ME2-induced HIF-1 suppression aggravates outcomes after global ischemia in rats (Zhou et al. 2008).

Several mechanisms have been proposed to explain HIF-1-mediated cytoprotective effects. HIF-1-induced EPO expression seems to be a crucial event to protect cells against hypoxic/ischemic injury. In vivo evidence showed that directly EPO administration into the brain reduces neurologic dysfunction in rodent models of stroke (Sadamoto et al. 1998; Sakanaka et al. 1998; Bernaudin et al. 1999; Sirén et al. 2001). Furthermore, neutralization of endogenous brain EPO potentiates ischemic brain injury, confirming a pivotal role for the endogenous EPO system in neuronal survival after ischemia (Sakanaka et al. 1998). A clinical trial conducted in 13 patients that received recombinant human EPO intravenously once daily for the first 3 days after stroke showed a reduction in the infarct size when compared with controls, this effect being associated with an improvement in clinical outcome (Ehrenreich et al. 2002). In addition, VEGF expression, another downstream gene of HIF-1, also counteracts detrimental ischemic injuries. Marti et al. (2000) demonstrated that the VEGF/VEGF receptor system, induced by hypoxia, leads to the growth of new vessels after cerebral ischemia, thereby minimizing the detrimental effects of cerebral ischemia (Marti et al. 2000). Accordingly, Jin et al. (2000) reported that VEGF also protected primary cultures of rat cerebral cortical neurons from hypoxia and glucose deprivation, being proposed that beyond its angiogenic properties, VEGF exert a direct neuroprotective effect in hypoxic-ischemic injury. There is also evidence showing that HIF-1 exerts anti-apoptotic effects through inhibition of cytochrome c release, caspase activation and poly (ADP-ribose) polymerase (PARP) cleavage, and the ability to suppress p53 activation (Li et al. 2004; Piret et al. 2004; Sasabe et al. 2005).

Additionally, brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor family that promotes the survival and differentiation of neuronal tissues, has been shown to exert neuroprotective effects in response to global and focal ischemia (Schabitz et al. 1997, 2000; Larsson et al. 1999). Shi et al. (2009) constructed an adenoviral vector using five copies of HRE found in the VEGF gene to regulate the expression of BDNF gene in a hypoxic condition. Shi et al. (2009) observed that adenovirus-mediated BDNF expression regulated by HRE protects brain against ischemia-induced injury. These results support the idea that HIF-1α could act as a sensor to express therapeutic genes in a cerebral ischemic stroke context.

Recently, Guo et al. (2009) observed that HIF-1 protect cells from ischemic injury by maintaining the cellular redox status. Guo et al. (2009) found that HIF-1α knockdown in SH-SY5Y cells down-regulates key enzymes in glucose metabolism that are critical in the production of important reducing agents, decreases GSH/GSSG ratio, increases ROS levels, and induces cell death under hypoxic or OGD conditions. Additionally, HIF-1 maintains cellular redox state and prevents ischemic injury mediated by ROS production, possibly through the up-regulation of the expression of key enzymes such as GLUT-1, glucose-6-phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase (Guo et al. 2009).

The IVS9-675C>A polymorphism of the HIF-1α gene was analyzed in patients with acute ischemic stroke and in a control group (Tupitsyna et al. 2006). Tupitsyna et al. (2006) found that this polymorphism potentiates the risk of stroke, which reinforce the idea that HIF-1 could be an effective therapeutic target for the development of pharmacological approaches to counteract stroke.

Alzheimer’s disease

Alzheimer’s disease is a progressive and fatal neurodegenerative disorder characterized by neuronal loss, cognitive dysfunction, and dementia. The pathological hallmarks of AD are the formation of extracellular senile plaques, mainly composed of β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein (Selkoe 2001; Moreira et al. 2006b). Aβ peptides are generated by successive proteolysis of amyloid-β precursor protein (AβPP), a large transmembrane glycoprotein that is initially cleaved by the β-site amyloid-β precursor protein (AβPP)-cleaving enzyme 1 and subsequently by γ-secretase in the transmembrane domain (Greenfield et al. 2000).

Glucose is the main source of energy required for normal brain function. As brain neurons are incapable to synthesize or store glucose, they are dependent on glucose transport across the blood–brain barrier, which is mediated by GLUTs (Scheepers et al. 2004). Accumulating evidence shows that glucose uptake and metabolism are impaired in the brain of AD patients. Moreover, this impairment seems to be a cause, rather than a consequence, of neurodegeneration in AD (Hoyer 2004). It has been demonstrated that impaired glucose uptake and metabolism leads to hyperphosphorylation of tau protein through the down-regulation of tau O-GlcNAcylation (Liu et al. 2004; Li et al. 2006). Recently, Liu et al. (2008) reported that GLUT-1 and GLUT-3, the two major brain GLUTs responsible for glucose uptake into neurons, were significantly decreased in AD brain, which contributes to abnormal hyperphosphorylation of tau and AD neurofibrillary degeneration. In addition, Liu et al. (2008) observed that HIF-1α protein levels were decreased. These results suggest that the decrease in GLUT-1 and GLUT-3 levels may result from the down-regulation of HIF-1α in AD brain. Recent findings also revealed that the induction of HIF-1 reduces astrocyte activation by Aβ peptide (Schubert et al. 2009) (Fig. 3). It was shown that Aβ-dependent astrocyte activation leads to a long-term decrease in HIF-1α expression and a reduction in the rate of glycolysis. Moreover, glial activation and the glycolytic changes are reversed by the maintenance of HIF-1α levels under conditions that prevent the proteasomal degradation of HIF-1α (Schubert et al. 2009).

Figure 3.

 Protective role of hypoxia-inducible factor 1 (HIF-1) in Alzheimer’s disease (AD). Experimental evidence show that the induction of HIF-1α by mimosine, desferoxamine and clioquinol reduces glial activation promoted by β-amyloid (Aβ) peptides inhibits Aβ deposition and improves brain glucose metabolism favoring neuronal survival.

Soucek et al. (2003) investigated the relation between HIF-1, Aβ, and glucose metabolism. The authors demonstrated that clonal nerve cell lines and primary cortical neurons that are resistant to Aβ toxicity have an enhanced flux of glucose through both the glycolytic pathway and the hexose monophosphate shunt (Fig. 3). Interestingly, the Aβ-induced changes in glucose metabolism are mediated by HIF-1 activation (Soucek et al. 2003). Indeed, preconditioning with low-dose Aβ (2 μM) or 50–100 μM mimosine, another HIF-1α inducer, rendered the neuronal cells resistant to toxicity mediated by subsequent lethal dose of Aβ (20 μM) through HIF-1α induction. In addition, activation of HIF-1 by the over-expression of a non-degradable HIF-1α prevented Aβ1-42-induced neurotoxicity, suggesting a neuroprotective role of HIF-1 in AD (Soucek et al. 2003).

Disruption of the metabolism of iron has been also associated with the pathogenesis of AD. Indeed, it has been shown an accumulation of iron in senile plaques and an altered distribution of iron transport and storage proteins in AD brains (Bishop et al. 2002). A previous in vitro study demonstrated that the pre-treatment of Aβ with the HIF-1 inducer and iron chelator DFO, attenuates neuronal toxicity, whereas its reconstitution with excess free iron restores cytotoxicity (Rottkamp et al. 2001). Furthermore, a single clinical trial conducted in AD patients subjected to intramuscular injections of DFO twice daily showed that this pharmacological activator of HIF-1 slowed cognitive decline by 50% in 2 years (Crapper McLachlan et al. 1991), suggesting that the administration of DFO may have some clinical relevance in preventing the progression of AD-associated dementia.

Copper (Cu) and Zinc (Zn) ions have also been shown to accumulate in the brains of AD patients (Atwood et al. 2000; Sayre et al. 2005; Moreira et al. 2006c). An in vivo study using APP2576 transgenic mice, an animal model of AD, revealed that oral treatment with CQ, a Cu/Zn chelator with the ability to induce HIF-1α, markedly inhibited Aβ deposition (49% decrease), in the absence of any marked neurotoxicity (Fig. 3) (Cherny et al. 2001). In a Phase II clinical trial, CQ slowed cognitive decline and decreased plasma Aβ levels in CQ-treated patients compared with those receiving the placebo (Ritchie et al. 2003).

Parkinson’s disease

Parkinson’s disease, the second most common neurodegenerative disorder, is characterized by a progressive and massive loss of midbrain dopaminergic (DA) neurons of the substantia nigra pars compacta (SNpc). Consequently, SNpc DA neuronal loss leads to the degeneration of neurons terminals and DA depletion in the striatum, which is required for normal motor function. One of the pathological hallmarks of PD and related synucleinopathies is the presence of intracellular inclusions called Lewy bodies, which are constituted by aggregates of the pre-synaptic soluble protein called α-synuclein (Cardoso et al. 2005). Additionally, iron levels in the SNpc have been reported to be elevated in PD patients (Sofic et al. 1988; Youdim et al. 1993). Accumulating evidence suggests that mitochondrial dysfunction, oxidative stress, neuroinflammation, excitotoxicity, and proteosomal dysfunction are also contributing factors for neuronal cell degeneration in PD (Beal 2003; Lin and Beal 2006; Nunomura et al. 2007).

In the early 1990s, Ben-Shachar et al. (1991) demonstrated that intracerebroventricular-injection of DFO protects against dopaminergic neurodegeneration induced by 6-hydroxydopamine in rats. Moreover, DFO pre-treatment prevents the manifestation of dopaminergic-related behavioral responses, such as spontaneous movements in a novel environment and rearing (Ben-Shachar et al. 1991). In addition, it was demonstrated that DFO also prevents neurotoxicity in the MPTP-mouse model of PD (Lan and Jiang 1997). Using this mouse model, Kaur et al. (2003) also demonstrated that animals treated for a period of 8 weeks with CQ exhibited a 30% decrease in iron levels in the substantia nigra and were protected against motor dysfunction compared with control animals. Moreover, CQ pre-treatment significantly attenuates the increase in oxidative stress markers and glutathione depletion induced by MPTP (Kaur et al. 2003).

A recent study demonstrated that 3,4-dihydroxybenzoate, a pharmacological inhibitor of PHDs, protects against in vitro and in vivo MPTP-induced neurotoxicity possible through the induction of HIF-1α (Lee et al. 2009). Indeed, Lee et al. (2009) observed that 3,4-dihydroxybenzoate treatment is capable to stabilize HIF-1α transcription factor, leading to the up-regulation of several proteins involved in iron efflux (ferroportin and heme oxygenase-1), DA synthesis (tyrosine hydroxylase) and mitochondrial integrity and bioenergetics (manganese superoxide dismutase, pyruvate dehydrogenase, and peroxisome proliferator-activated receptor-γ coactivator-1α), cell components that are compromised in PD. Therefore, these data reinforce the idea that the pharmacological induction of HIF-1α could have neuroprotective effects, in this specific case with a beneficial impact on DA synthesis, iron homeostasis, antioxidant defenses and mitochondrial dysfunction (Fig. 4).

Figure 4.

 Protective role of hypoxia-inducible factor 1 (HIF-1) in Parkinson’s disease (PD). Clioquinol, desferoxamine and 3,4-dihydroxybenzoate, pharmacological inhibitiors of prolyl hydroxylase enzymes (PHDs), promote neuroprotection through the induction of HIF-1α. The induction of HIF-1α improves dopamine (DA) synthesis, iron homeostasis and antioxidant defenses and prevents mitochondrial dysfunction. Additionally, HIF-1α induction ameliorates motor functions in mouse models of PD.

Huntington’s disease

Huntington’s disease, an autosomal dominant disease, is a severe movement disorder characterized by cognitive decline and early death. HD results from an abnormal expanded polyglutamine repeat in the huntingtin (htt) protein, which leads to the degeneration of the neurons of the striatum and cortex (Ross et al. 1997).

Mitochondrial dysfunction in neurons and glia cells appears to be intimately involved in the pathogenesis of HD. Panov et al. (2002) demonstrated that lymphoblast mitochondria from HD patients have a lower membrane potential and depolarize at lower calcium loads than mitochondria from controls. Moreover, Panov et al. (2002) observed that brain mitochondria from transgenic mice expressing full-length mutant htt also showed similar mitochondrial calcium defects, which preceded the onset of pathological or behavioral abnormalities by months. In addition, the brains of 12-week-old transgenic mouse model of HD (R6/2) demonstrated a significant reduction in aconitase and mitochondrial complex IV activities in the striatum and a decrease in complex IV activity in the cerebral cortex (Tabrizi et al. 2000). It has been shown that chronic administration of 3-nitropropionic acid, a mitochondrial toxin that irreversibly inhibits the succinate dehydrogenase, in rats produces selective striatal lesions that replicate many of the histological and neurochemical features of HD (Beal et al. 1993). It was demonstrated that the preconditioning of rat C6 astroglial cells with the HIF-1 inducers, CoCl2, mimosine, and DFO exerted substantial cytoprotective effects against metabolic insults induced by 3-nitropropionic acid exposure (Yang et al. 2005). Moreover, it was observed that application of cadmium chloride capable of neutralizing cobalt-induced HIF-1 activation, HIF-specific oligodeoxynucleotide decoy, and antisense phosphorothioate oligodeoxynucleotide against HIF-1α abolished the protective effect induced by CoCl2 preconditioning (Yang et al. 2005). These findings suggest that induction of HIF-1 and its downstream genes could mediate neuroprotective events in neurodegenerative disorders, such as HD, in which mitochondrial dysfunction plays a prominent role (Yang et al. 2005). Finally, Nguyen et al. (2005) demonstrated the beneficial effects of CQ treatment to reduce cell death and mutant protein accumulation using in vitro models of HD. Moreover, CQ treatment of transgenic HD mice R6/2 improved behavioral and pathologic phenotypes, decreased htt aggregates accumulation and striatal atrophy, improved rotarod performance, reduced weight loss, normalized blood glucose and insulin levels, and extended lifespan (Nguyen et al. 2005).

Concluding Remarks

HIF-1 has a pivotal role in physiological adaptive responses to hypoxia, modulating several metabolic pathways. Therefore, this transcription factor could be an attractive and feasible target of therapeutic interventions to prevent or mitigate pathophysiological conditions, such as neurodegenerative diseases. Evidence demonstrated that mild hypoxic preconditioning and hypoxia-mimetic agents have beneficial effects not only in cerebral ischemic stroke but also in some neurodegenerative disorders including AD, PD and HD. Elucidation of the molecular mechanisms involved in HIF-1 signaling pathway regulation is crucial to develop new pharmacological interventions aimed to minimize or delay neurodegeneration.

Ancillary